BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bouzid R, Peppelenbosch M, Buschow SI. Opportunities for Conventional and in Situ Cancer Vaccine Strategies and Combination with Immunotherapy for Gastrointestinal Cancers, A Review. Cancers (Basel) 2020;12:E1121. [PMID: 32365838 DOI: 10.3390/cancers12051121] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Sahu BP, Baishya R, Hatiboruah JL, Laloo D, Biswas N. A comprehensive review on different approaches for tumor targeting using nanocarriers and recent developments with special focus on multifunctional approaches. J Pharm Investig . [DOI: 10.1007/s40005-022-00583-x] [Reference Citation Analysis]
2 Zhang S, Li S, Wei Y, Xiong Y, Liu Q, Hu Z, Zeng Z, Tang F, Ouyang Y. Identification of Potential Antigens for Developing mRNA Vaccine for Immunologically Cold Mesothelioma. Front Cell Dev Biol 2022;10:879278. [DOI: 10.3389/fcell.2022.879278] [Reference Citation Analysis]
3 Hao Y, Chung CK, Yu Z, Huis In 't Veld RV, Ossendorp FA, Ten Dijke P, Cruz LJ. Combinatorial Therapeutic Approaches with Nanomaterial-Based Photodynamic Cancer Therapy. Pharmaceutics 2022;14:120. [PMID: 35057015 DOI: 10.3390/pharmaceutics14010120] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
4 Wang Y, Tan H, Yu T, Chen X, Jing F, Shi H. Potential Immune Biomarker Candidates and Immune Subtypes of Lung Adenocarcinoma for Developing mRNA Vaccines. Front Immunol 2021;12:755401. [DOI: 10.3389/fimmu.2021.755401] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Ma S, Ba Y, Ji H, Wang F, Du J, Hu S. Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development. Front Immunol 2021;12:738435. [PMID: 34603319 DOI: 10.3389/fimmu.2021.738435] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
6 Chu Y, Li R, Qian L, Liu F, Xu R, Meng F, Ke Y, Shao J, Yu L, Liu Q, Liu B. Tumor eradicated by combination of imiquimod and OX40 agonist for in situ vaccination. Cancer Sci 2021. [PMID: 34537997 DOI: 10.1111/cas.15145] [Reference Citation Analysis]
7 Zhong H, Liu S, Cao F, Zhao Y, Zhou J, Tang F, Peng Z, Li Y, Xu S, Wang C, Yang G, Li ZQ. Dissecting Tumor Antigens and Immune Subtypes of Glioma to Develop mRNA Vaccine. Front Immunol 2021;12:709986. [PMID: 34512630 DOI: 10.3389/fimmu.2021.709986] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
8 Wang DK, Zuo Q, He QY, Li B. Targeted Immunotherapies in Gastrointestinal Cancer: From Molecular Mechanisms to Implications. Front Immunol 2021;12:705999. [PMID: 34447376 DOI: 10.3389/fimmu.2021.705999] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
9 Mao C, Gorbet MJ, Singh A, Ranjan A, Fiering S. In situ vaccination with nanoparticles for cancer immunotherapy: understanding the immunology. Int J Hyperthermia 2020;37:4-17. [PMID: 33455477 DOI: 10.1080/02656736.2020.1810333] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
10 Han L, Peng K, Qiu LY, Li M, Ruan JH, He LL, Yuan ZX. Hitchhiking on Controlled-Release Drug Delivery Systems: Opportunities and Challenges for Cancer Vaccines. Front Pharmacol 2021;12:679602. [PMID: 34040536 DOI: 10.3389/fphar.2021.679602] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
11 Lurje I, Werner W, Mohr R, Roderburg C, Tacke F, Hammerich L. In Situ Vaccination as a Strategy to Modulate the Immune Microenvironment of Hepatocellular Carcinoma. Front Immunol 2021;12:650486. [PMID: 34025657 DOI: 10.3389/fimmu.2021.650486] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
12 Lin W, Li C, Xu N, Watanabe M, Xue R, Xu A, Araki M, Sun R, Liu C, Nasu Y, Huang P. Dual-Functional PLGA Nanoparticles Co-Loaded with Indocyanine Green and Resiquimod for Prostate Cancer Treatment. Int J Nanomedicine 2021;16:2775-87. [PMID: 33880023 DOI: 10.2147/IJN.S301552] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
13 Huang X, Zhang G, Tang T, Liang T. Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development. Mol Cancer 2021;20:44. [PMID: 33648511 DOI: 10.1186/s12943-021-01310-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 35] [Article Influence: 3.0] [Reference Citation Analysis]